Cargando…
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar
BACKGROUND AND OBJECTIVE: To assess the dosimetric feasibility of a stereotactic body radiotherapy (SBRT) dose escalated protocol, with a simultaneous integrated boost (SIB) and a simultaneous integrated protection (SIP) approach, in patients with locally advanced pancreatic cancer (LAPC). MATERIAL...
Autores principales: | Mazzarotto, Renzo, Simoni, Nicola, Guariglia, Stefania, Rossi, Gabriella, Micera, Renato, De Robertis, Riccardo, Pierelli, Alessio, Zivelonghi, Emanuele, Malleo, Giuseppe, Paiella, Salvatore, Salvia, Roberto, Cavedon, Carlo, Milella, Michele, Bassi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773844/ https://www.ncbi.nlm.nih.gov/pubmed/33392093 http://dx.doi.org/10.3389/fonc.2020.600940 |
Ejemplares similares
-
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer
por: Rossi, Gabriella, et al.
Publicado: (2021) -
Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy
por: Rossi, Gabriella, et al.
Publicado: (2022) -
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma
por: Paiella, Salvatore, et al.
Publicado: (2021) -
Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?
por: Simoni, Nicola, et al.
Publicado: (2022) -
(18)F-FDG PET/CT Metrics Are Correlated to the Pathological Response in Esophageal Cancer Patients Treated With Induction Chemotherapy Followed by Neoadjuvant Chemo-Radiotherapy
por: Simoni, Nicola, et al.
Publicado: (2020)